Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

NCT06113471 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT06113471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06113471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 27, 2023
Completion date
March 16, 2027
Enrollment
450 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

nonsegmental vitiligo